EASD 2022 "Any patient that has HFmrEF or HFpEF is going to benefit from dapaglifozin regardless of glycemic status and regardless of background diabetes therapy", says Prof. Jhund.
EASD 2022 A prespecified secondary analysis was performed to investigate whether muscle fat infiltration -associated with increased risk of HF- can be modified by treatment with liraglutide in patients with overweight or obesity.
EASD 2022 A post-hoc analysis of EMPA-REG OUTCOME examined the effect of empagliflozin on changes in risk of progression to ESKD by assessing worsening and improvement in KDIGO risk groups.
EASD 2022 It is not known whether a higher intake of sodium and protein may lead to a higher extent of early dip in GFR in T2DM patients who started an SGLT2 inhibitor. A pilot study was undertaken with 28 subjects.
EASD 2022 A post hoc analysis showed that semaglutide reduces CV risk across all strata of kidney function and kidney damage in patients with T2DM who are at high CV risk.
EASD 2022 This pooled post hoc analysis of SUSTAIN 6 and PIONEER 6 showed that that semaglutide consistently reduced the risk of MACE across eGFR and UACR subgroups in patients with T2DM who are at high CV risk.
EASD 2022 In patients with new onset T2DM in the DD2 cohort, high CRP was a better marker of all-cause mortality than future CV events, whereas high C-peptide was a better marker of increased CV risk.
ESC 2022 A prespecified exploratory FIDELITY subanalysis investigated the causes of death in patients with CKD and T2DM who were either treated with finerenone or placebo.
ESC 2022 Prof. Solomon summarizes the results of the DELIVER trial. “We believe that these data support the use of SGLT2i as foundational therapy in patients with HF, regardless of care setting or ejection fraction” said Prof. Solomon.
ESC 2022 The DELIVER trial shows that dapagliflozin reduced the risk of CV death or worsening HF in patients with HFmrEF or HFpEF, with no attenuation of treatment benefit in patients with the highest EF.
ESC 2022 A pooled analysis of DAPA-HF and DELIVER was undertaken to examine the effect of dapagliflozin in patient with heart failure across the entire spectrum of ejection fraction.
Two meta-analyses were performed including SGLT2i trials in HF patients: one including DELIVER and EMPEROR-Preserved and the other one of the 5 trials DELIVER, EMPEROR-Preserved, DAPA-HF, EMPEROR-Reduced and SOLOIST-WHF.